Found: 22
Select item for more details and to access through your institution.
Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives.
- Published in:
- Pharmacotherapy, 2009, v. 29, n. 8, p. 924, doi. 10.1592/phco.29.8.924
- By:
- Publication type:
- Article
Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 8, p. 1025, doi. 10.1002/jcph.1112
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 5, p. 896, doi. 10.1111/cts.12840
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Stavudine in HIV-Infected Pregnant Women and Their Infants: Pediatric AIDS Clinical Trials Group Protocol 332.
- Published in:
- Journal of Infectious Diseases, 2004, v. 190, n. 12, p. 2167, doi. 10.1086/425903
- By:
- Publication type:
- Article
Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 376, doi. 10.1002/cpdd.870
- By:
- Publication type:
- Article
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 32, doi. 10.1002/cpdd.755
- By:
- Publication type:
- Article
A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 641, doi. 10.1002/cpdd.390
- By:
- Publication type:
- Article
Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
- Published in:
- Clinical Infectious Diseases, 2018, v. 67, n. 6, p. 934, doi. 10.1093/cid/ciy201
- By:
- Publication type:
- Article
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
- Published in:
- Liver International, 2016, v. 36, n. 8, p. 1101, doi. 10.1111/liv.13082
- By:
- Publication type:
- Article
Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3211, doi. 10.1111/bcp.15239
- By:
- Publication type:
- Article
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
- Published in:
- Clinical Pharmacokinetics, 2015, v. 54, n. 7, p. 677, doi. 10.1007/s40262-015-0261-7
- By:
- Publication type:
- Article
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
- Published in:
- Japanese Journal of Clinical Oncology, 2020, v. 50, n. 12, p. 1395, doi. 10.1093/jjco/hyaa153
- By:
- Publication type:
- Article
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 5, p. 1334, doi. 10.1002/cpt.2105
- By:
- Publication type:
- Article
Physiologically‐Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID‐19.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 4, p. 1116, doi. 10.1002/cpt.2176
- By:
- Publication type:
- Article
Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 6, p. 1182, doi. 10.1002/cpt.1073
- By:
- Publication type:
- Article
Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 104, n. 6, p. 1191, doi. 10.1002/cpt.1072
- By:
- Publication type:
- Article